Related Topics News -

     
 Detail   |   Print    Next page > 
     
《業績》維昇藥業全年虧損擴至2.53億人民幣
2026-03-13T  
《大行》大摩對中資生物醫藥股投資評級及目標價(表)
2026-03-03T  
維昇藥業隆培生長激素獲生物製品上市許可
2026-01-26T  
維昇藥業委任首席財務官
2025-10-13T  
《大行》大摩對生物科技股投資評級及目標價(表)
2025-09-22T  
《大行》大摩:市場對生物科技股認可度提升 推動股價跑贏大市
2025-09-22T  
《業績》維昇藥業半年虧損擴大至1.18億人幣 不派息
2025-08-28T  
維昇藥業穩定價格期結束 超額配股權失效
2025-04-21T  
《新股》維昇藥業-B全日收68.8元
2025-03-21T  
《新股》維昇藥業-B半日收67.2元 低上市價2.3%
2025-03-21T  
  Next page > 

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.